Dolopar Plus Uses

sponsored
Did you have any side effects with this medicine?

What is Dolopar Plus?

Dolopar Plus (acetaminophen and propoxyphene) was withdrawn from the U.S. market in November 2010.

Dolopar Plus contains a combination of propoxyphene and acetaminophen. Propoxyphene is in a group of drugs called narcotic pain relievers. Acetaminophen is a less potent pain reliever and a fever reducer that increases the effects of propoxyphene.

Dolopar Plus is used to relieve mild to moderate pain with or without fever.

Dolopar Plus may also be used for purposes not listed in this medication guide.

Dolopar Plus indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or Paracetamol (Dolopar Plus) is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of Paracetamol (Dolopar Plus). A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Reduction of fever. Relief of aches & pains associated w/ flu, common colds, tonsilitis, teething pains & post-immunization reactions.

Dolopar Plus description

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Dolopar Plus is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)

Dolopar Plus dosage

Dolopar Plus-N is intended for the management of mild to moderate pain. The dose should be individually adjusted according to severity of pain, patient response and patient size.

Dolopar Plus-N 100 (100 mg propoxyphene napsylate and 650 mg acetaminophen)

The usual dosage is one tablet every 4 hours orally as needed for pain. The maximum dose of Dolopar Plus-N 100 is 6 tablets per day. Do not exceed the maximum daily dose.

Dolopar Plus-N 50 (50 mg propoxyphene napsylate and 325 mg acetaminophen)

The usual dosage is two tablets every 4 hours orally as needed for pain. The maximum dose of Dolopar Plus-N 50 is 12 tablets per day. Do not exceed the maximum daily dose.

Patients receiving propoxyphene and any CYP3A4 inhibitor should be carefully monitored for an extended period of time and dosage adjustments should be made if warranted.

Consideration should be given to a reduced total daily dosage in elderly patients and in patients with hepatic or renal impairment.

Cessation of Therapy

For patients who used Dolopar Plus-N on a regular basis for a period of time, when therapy with Dolopar Plus-N is no longer needed for the treatment of their pain, it may be useful to gradually discontinue the Dolopar Plus-N over time to prevent the development of an opioid abstinence syndrome (narcotic withdrawal). In general, therapy can be decreased by 25% to 50% per day with careful monitoring for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, the dose should be raised to the previous level and titrated down more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.

Dolopar Plus interactions

See also:
What other drugs will affect Dolopar Plus?

sponsored

In vitro results suggest that methadone undergoes hepatic N-demethylation by cytochrome P450 enzymes, principally CYP3A4, CYP2B6, CYP2C19 and to a lesser extent by CYP2C9 and CYP2D6. Coadministration of methadone with CYP inducers of these enzymes may result in a more rapid metabolism and potential for decreased effects of methadone, whereas administration with CYP inhibitors may reduce metabolism and potentiate methadones effects. Although antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination are known to inhibit CYPs, they are shown to reduce the plasma levels of methadone, possibly due to their CYP induction activity. Therefore, drugs administered concomitantly with methadone should be evaluated for interaction potential; clinicians are advised to evaluate individual response to drug therapy.

Opioid Antagonists, Mixed Agonist/Antagonists, and Partial Agonists

As with other mu-agonists, patients maintained on methadone may experience withdrawal symptoms when given opioid antagonists, mixed agonist/antagonists, and partial agonists. Examples of such agents are naloxone, naltrexone, pentazocine, nalbuphine, butorphanol, and buprenorphine.

Anti-retroviral Agents

Abacavir, amprenavir, efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination - Coadministration of these anti-retroviral agents resulted in increased clearance or decreased plasma levels of methadone. Dolopar Plus-maintained patients beginning treatment with these antiretroviral drugs should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly.

Didanosine and Stavudine - Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Dolopar Plus disposition was not substantially altered.

Zidovudine - Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.

Cytochrome P450 Inducers

Dolopar Plus-maintained patients beginning treatment with CYP3A4 inducers should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly. The following drug interactions were reported following coadministration of methadone with inducers of cytochrome P450 enzymes:

Rifampin - In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.

Phenytoin - In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.

St. Johns Wort, Phenobarbital, Carbamazepin/strong>Administration of methadone along with other CYP3A4 inducers may result in withdrawal symptoms.

Cytochrome P450 Inhibitors

Since the metabolism of methadone is mediated primarily by CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of methadone. The expected clinical results would be increased or prolonged opioid effects. Thus, methadone-treated patients coadministered strong inhibitors of CYP3A4, such as azole antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), with methadone should be carefully monitored and dosage adjustment should be undertaken if warranted. Some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) may increase methadone plasma levels upon coadministration with methadone and result in increased opiate effects and/or toxicity.

Voriconazole - Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed.

Others

Monoamine Oxidase (MAO) Inhibitors - Therapeutic doses of meperidine have precipitated severe reactions in patients concurrently receiving monoamine oxidase inhibitors or those who have received such agents within 14 days. Similar reactions thus far have not been reported with methadone. However, if the use of methadone is necessary in such patients, a sensitivity test should be performed in which repeated small, incremental doses of methadone are administered over the course of several hours while the patients condition and vital signs are under careful observation.

Desipramine - Blood levels of desipramine have increased with concurrent methadone administration.

Potentially Arrhythmogenic Agents

Extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone. Pharmacodynamic interactions may occur with concomitant use of methadone and potentially arrhythmogenic agents such as class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers.

Caution should also be exercised when prescribing methadone concomitantly with drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia) that may prolong the QT interval. These drugs include diuretics, laxatives, and, in rare cases, mineralocorticoid hormones.

Interactions with Alcohol and Drugs of Abuse

Dolopar Plus may be expected to have additive effects when used in conjunction with alcohol, other opioids or CNS depressants, or with illicit drugs that cause central nervous system depression. Deaths have been reported when methadone has been abused in conjunction with benzodiazepines.

Anxiety - Since methadone as used by tolerant patients at a constant maintenance dosage does not act as a tranquilizer, patients who are maintained on this drug will react to life problems and stresses with the same symptoms of anxiety as do other individuals. The physician should not confuse such symptoms with those of narcotic abstinence and should not attempt to treat anxiety by increasing the dose of methadone. The action of methadone in maintenance treatment is limited to the control of narcotic withdrawal symptoms and is ineffective for relief of general anxiety.

Acute Pain - Maintenance patients on a stable dose of methadone who experience physical trauma, postoperative pain or other acute pain cannot be expected to derive analgesia from their existing dose of methadone. Such patients should be administered analgesics, including opioids, in doses that would otherwise be indicated for non-methadone-treated patients with similar painful conditions. Due to the opioid tolerance induced by methadone, when opioids are required for management of acute pain in methadone patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients.

Risk of Relapse in Patients on Dolopar Plus Maintenance Treatment of Opioid Addiction

Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms. Presentation of these symptoms have been associated with an increased risk of susceptible patients to relapse to illicit drug use and should be considered when assessing the risks and benefit of methadone use.

Tolerance and Physical Dependence

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and/or tolerance are not unusual during chronic opioid therapy.

If methadone is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, chronically administered methadone should not be abruptly discontinued.

Special-Risk Patients

Dolopar Plus should be given with caution and the initial dose reduced in certain patients, such as the elderly and debilitated and those with severe impairment of hepatic or renal function, hypothyroidism, Addisons disease, prostatic hypertrophy, or urethral stricture. The usual precautions appropriate to the use of parenteral opioids should be observed and the possibility of respiratory depression should always be kept in mind.

Dolopar Plus side effects

See also:
What are the possible side effects of Dolopar Plus?

sponsored

Dizziness, sedation, nausea, vomiting, weakness, constipation, abdominal pain, rash, euphoria, dysphoria, visual disturbances, liver dysfunction, abuse potential.

Potentially Fatal: Hepatic necrosis (especially in chronic alcoholics).

Dolopar Plus contraindications

See also:
What is the most important information I should know about Dolopar Plus?

Dolopar Plus is contraindicated in patients with a known hypersensitivity to methadone hydrochloride or any other ingredient in DOLOPHINE.

Dolopar Plus is contraindicated in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), and in patients with acute bronchial asthma or hypercarbia.

Dolopar Plus is contraindicated in any patient who has or is suspected of having a paralytic ileus.

Active ingredient matches for Dolopar Plus:

Dextropropoxyphene/Paracetamol

Caffeine/Dextropropoxyphene/Paracetamol


Unit description / dosage (Manufacturer)Price, USD
Dolopar Plus Dextropropoxyphene65mg, Paracetamol 400mg TAB / 10$ 0.19
Dolopar Plus 400+65 Tablet$ 0.02
Dolopar Plus Dextropropoxyphene65mg, Paracetamol 400mg TAB / 10$ 0.19
DOLOPAR PLUS CAPSULE 1 strip / 10 capsules each (Micro Labs Ltd)$ 0.42
Dolopar Plus Capsule (Micro Labs Ltd)$ 0.04

List of Dolopar Plus substitutes (brand and generic names):

Dolocin 1, 000's$ 300.00
Dolpocetmol 500's
Dolpocetmol 1, 000's
Dolpocetmol 1's
LUPIVON Capsule/ Tablet / 70mg - 400mg / 8 units (Lupin Laboratories)$ 0.16
Lupivon Paracetamo, Dextropropoxyphene TAB / 8$ 0.17
8's$ 0.17
Lupivon Paracetamol, Dextropropoxyphene. TAB / 8$ 0.17
Lupivon Paracetamol, Dextropropoxyphene. TAB / 8$ 0.17
Lupivon Paracetamo, Dextropropoxyphene TAB / 8$ 0.17
Medonol 5 x 50's
Medonol 500's
Tablet; Oral; Acetaminophen 500 mg; Dextropropoxyphene Hydrochloride 65 mg
PAINVON CAPSULE 1 strip / 8 capsules each (Intas Pharmaceuticals Ltd)$ 0.13
Tablet; Oral; Acetaminophen; Dextropropoxyphene Hydrochloride
PARVON N 350MG/32MG CAPSULE 1 packet / 100 capsules each (Jagsonpal Pharmaceuticals Ltd)$ 0.99
Parvon N Capsule (Jagsonpal Pharmaceuticals Ltd)$ 0.01
100 tablet in 1 bottle
500 tablet in 1 bottle
PROXYNOVA CAPSULE 1 strip / 8 capsules each (Zydus Cadila)$ 0.26
PROXYVON Capsule/ Tablet / 65mg - 400mg / 8 units (Wockhardt)$ 0.25
Proxyvon Paracetamol 500mg, Dextropropoxyphene HCI 32.5mg FC-TAB / 10$ 0.11
Proxyvon Paracetamol 400mg, Dextropropoxyphene 65mg CAP / 8$ 0.26
8's$ 0.17
10's$ 0.11
Proxyvon 24 Tablet
Proxyvon 18 Blister x 8 Tablet
Proxyvon 24 Tablet nang 1
Proxyvon 18 Blister x 8 Tablet nang 2
Proxyvon Paracetamol 400 mg, Dextropropoxyphene napsilate100 mg. CAP / 8$ 0.26
Proxyvon Paracetamol 500 mg, Dextropropoxyphenehydrochloride 32.5 mg. FC-TAB / 10$ 0.11
PYEEVON SPAS CAPSULE 1 strip / 10 capsules each (Laborate Pharmaceuticals India Ltd)$ 0.21
SUDHINOL Capsule/ Tablet / 65mg - 650mg / 10 units (Rextar (Ranbaxy Laboratories Ltd))$ 0.32
Sudhinol Paracetamol 650mg, Dextropropoxyphene 65mg TAB / 10 (Rextar (Ranbaxy Laboratories Ltd))$ 0.32

References

  1. DailyMed. "PROPOXYPHENE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. PubChem. "caffeine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Dolopar Plus are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Dolopar Plus. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 21 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved